Novo Undercuts Lilly’s Obesity Drug Price for Cash

November 17, 2025

•

1 min read

•

Bloomberg.com

Novo Nordisk A/S is undercutting arch-rival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness to compete on price as it tries to claw back a larger share of the US market.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world Connecting decision makers to a dynamic network of infor... [792 chars]

Read Original Article

Source: Bloomberg.com

Visit Source

Share this article

Twitter Facebook

Back to business news